公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulinactive pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
公司地址 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
電話號碼 +1 909 980-9484
傳真號碼 --
公司網頁 https://www.amphastar.com
員工數量 1976
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. William J. Peters Director, Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems Limited 美元 649.85K 13/04/2026
Dr. Jack Yongfeng Zhang, PhD Director, President, Chief Executive Officer and Chief Scientific Officer 美元 950.91K 13/04/2026
Dr. Mary Ziping Luo, PhD Chairman of the Board, Chief Operating Officer and Chief Scientist 美元 775.12K 13/04/2026
Mr. Rong Zhou Senior Executive Vice President, Production; President of Amphastar Nanjing Pharmaceuticals, Co., Ltd. 美元 717.59K 13/04/2026
Mr. Jacob Liawatidewi Executive Vice President, Sales and Marketing and Corporate Administration Center;President of Amphastar France Pharmaceuticals, S.A.S 美元 499.91K 13/04/2026
 
董事會成員
董事會 職務 更新日期
Dr. Howard S. Lee, PhD Independent Director 13/04/2026
Mr. Richard Prins Lead Independent Director 13/04/2026
Mr. William J. Peters Director, Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems Limited 13/04/2026
Mr. David Gaugh Independent Director 13/04/2026
Dr. Jack Yongfeng Zhang, PhD Director, President, Chief Executive Officer and Chief Scientific Officer 13/04/2026
Dr. Mary Ziping Luo, PhD Chairman of the Board, Chief Operating Officer and Chief Scientist 13/04/2026
Dr. Michael A. Zasloff, M.D.,PhD Independent Director 13/04/2026
Mr. Floyd F. Petersen, M.P.H. Independent Director 13/04/2026
Ms. Diane G. Gerst Independent Director 13/04/2026
Mr. Jacob Liawatidewi Executive Vice President, Sales and Marketing and Corporate Administration Center;President of Amphastar France Pharmaceuticals, S.A.S 13/04/2026
Ms. Gayle M. Deflin Independent Director 13/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:35)
代號 名稱 佔比% 持有日期
QVMSInvesco S&P SmallCp 600 QVM Mlt-fctr ETF0.01%29/04/2026
DFUSDimensional US Equity Market ETF0.01%29/04/2026
CAFGPacer US Small Cap Cash Cows Gr Ldrs ETF0.01%29/04/2026
DFAUDimensional US Core Equity Market ETF0.01%29/04/2026
DCORDimensional US Core Equity 1 ETF0.01%29/04/2026
TILTFlexShares Mstar US Mkt Factors Tilt ETF0.01%29/04/2026
XJRiShares ESG Select Scrn S&P Small-CapETF0.01%29/04/2026
SQLVRoyce Quant Small-Cap Quality Value ETF0.01%28/04/2026
WSMLiShares MSCI World Small-Cap ETF0.01%28/04/2026
VTHRVanguard Russell 3000 ETF0.01%31/03/2026
VTWGVanguard Russell 2000 Growth ETF0.01%31/03/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%29/04/2026
SMDXIntech S&P Small-Mid Cap Divers Alp ETF0.004%29/04/2026
BIBProShares Ultra Nasdaq Biotechnology0.004%29/04/2026
ITWOProShares Russell 2000 High Income ETF0.004%29/04/2026
IVSSApplied Finance IVS US SMID ETF0.004%29/04/2026
URTYProShares UltraPro Russell20000.003%29/04/2026
ISCBiShares Morningstar Small-Cap ETF0.003%29/04/2026
DXUVDimensional US Vector Equity ETF0.003%29/04/2026
UWMProShares Ultra Russell20000.003%29/04/2026
  1    2    3   4    5    6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.